|
Post by saxcmann on Jan 31, 2017 14:18:04 GMT -5
There is no doubt Mannkind has a huge marketing problem and pricing is part of that problem. If afrezza was meant to be used as 1 cartridge per meal, Mike C. may be right and afrezza is actually cheaper. But Mike is not. For afrezza to exceed RAA A1c values a second dose is often required to mimic phase 2 insulin release. When you add in corrections and snacks a better estimate is at least 180 cartridges per month. Afrezza is now sold as 4/8/12 units. Al talked about the 16u and the new process to allow it. I think they need to not only make the 16u but a 1u and 2u for corrections and for the kids. IMO, Mannkind needs to rework packaging and the way it is priced and come in at a 20% lower price point to RAAs to gain some traction. Good points sayhey. I'd do 2u and 18u only. I'd lower the price by 15% from other RAAs. I would target more PCPs and schedule a lot more lunch and learns in offices. "Ultra" label will make a big difference selling docs.
|
|
|
Post by saxcmann on Jan 30, 2017 14:10:59 GMT -5
Dexcom pays a little upfront because maybe they would like to be associated with Afrezza before Medtronic. Eventually this awesome combine solution to Diabetes care will be the standard of care for Type 1's : Basal - Tresiba? Prandial - Afrezza CMG - Dexcom? Potentially these three companies can combine efforts and a price to allow the best solution for Diabetics. For Type 2's and maybe Pre-Diabetics down the road you will see a shift in treatment to a non-invasive CGM and Afrezza at mealtimes. If I am a CGM company I would like to partner with the fastest real-time prandial insulin. That only makes my CGM product that much better. I would be willing to put a little cash up to start that relationship instead of my competitors starting that relationship. Yes, yes, and yes! Now I hearya talking jmkopp! Mnkd management usually doesn't do what i(we) think but at least someone else on this board thinks the same way! Lol
|
|
|
Post by saxcmann on Jan 30, 2017 11:21:00 GMT -5
I am betting on this announcement including a small co-promotional marketing agreement with Dexcom. The ramp up in sales force along with Matt alluding to the sales force potentially selling another product in the past lead me to believe this is what will be announced. I also think they will provide some additional small updates on the hiring process. Dexcom and it's CGM makes the most sense to co-promote. I anticipate a small (10-20 million) upfront payment from Dexcom. But, it is the strategic relationship and discussion surrounding it that is going to be important moving forward; unfortunately not the money component of this deal. I am not certain the Dexcom CGM is perfect; however, once a non-invasive CGM is marketed and is covered by insurance companies for type 2 Diabetics as well as type 1's this Company will take off big time. This will be a good step in the right direction. We just need the money to sustain us until sales creep up. I also think there might be potential for the announcement of a partner for inhaled epinephrine. If it is not at this meeting it will be soon. It would be great timing and would generate a lot of buzz in the market. The money received up front in this type of a deal could really carry us forward another 6-9 months. For better or worse; I am all in and fully believe MNKD will become a giant in the pharmaceutical world. GLTA Nice post! I agree.
|
|
|
Post by saxcmann on Jan 30, 2017 8:49:20 GMT -5
My guess is some type of co-promotion deal with dexcom.
Please do not mark my post. Only a guess. 😊
|
|
|
Post by saxcmann on Jan 29, 2017 10:42:42 GMT -5
Hi SportsRancho, For me what confirms that MNKD management knew that the SP would go below $1.00 and delisting will be an issue....is the fact that they went to get listing on the TASE exchange. It is oubious to me that they knew it and TASE is part of the plan of action..so consider a delisting from the NASDAQ Cheers, Sylvaing, I'm very confident you don't know what your talking about. You must be bored this morning? I think Sports has a good feel what's going on. I can assure you that you don't. I can confirm mnkd management did not know pps will go below $1 and delisting would be an issue. Ridiculous comments.
|
|
|
Post by saxcmann on Jan 27, 2017 13:35:44 GMT -5
On 12/13/16 Rose said, On the 11/9 call, our CMO stated that our current lead candidate is our inhaled epinephrine. With limited resources, we are focused on the clinical development program and post-marketing requirements for Afrezza and this lead candidate in the near term. As we’ve stated before, if there are partnering opportunities, we would announce them. You must appreciate that product candidates need to reach a level of value before any potential partner would be interested. We are focused on getting inhaled epi to that stage. Read more: mnkd.proboards.com/thread/6408/mnkd-state-union?page=17#ixzz4WzE2CRsXIt's EpiHale partnership most likely. Can anyone guess upfront cash effect vs pps? In my opinion upfront cash would need to be minimum $30-$50 million to move pps above $1.
|
|
|
Post by saxcmann on Jan 26, 2017 13:12:11 GMT -5
I'm about a 4 right now. With mnkd management history and current information about pipeline, that's about my confidence level today.
|
|
|
Post by saxcmann on Jan 23, 2017 11:48:04 GMT -5
One thing I don't quite understand. Who is in the field selling afrezza while MNKD is training new reps? Is Publicis still in the picture? Yes, a little lull in action...
|
|
|
Post by saxcmann on Jan 22, 2017 10:29:38 GMT -5
Why not have one less rep and pay one person to fly all over the US giving presentations? There were also doctors that were to give dinner talks. I'm not sure they ever happened... I'm hoping they're swamped with all the other things they have in the works! lol.. I couldnt come up with any such things . Scheduling a presentation takes 10 min... even 4 weeks out of the day... Scheduling was not the problem, iam2 Maybe 2 reps less for one person to fly around, Sports. I think they are swamped with hiring and training new reps.
|
|
|
Post by saxcmann on Jan 20, 2017 9:10:03 GMT -5
To me it simply suggests mnkd management thinks they'll get an extension. Like Aged post implies they can't say much more than that...
|
|
|
Post by saxcmann on Jan 17, 2017 18:01:03 GMT -5
I think this is big news! More patients using CGMs only helps prove how afrezza works and keep PWD in control of their blood sugars. Me too. However this is approved for T1 and T2 not just T1s from what I am seeing. From Dexcom dexcom.com/news/dexcom-cgm-medicare also the CMS document says it is for T1 and T2s. Also in the CMS document is payment info. It looks like $277 is the top of the reimbursement for the CGM and then about $250 per month to cover the sensors - if I am reading this correctly which I may not be cms.gov/Regulations-and-Guidance/Guidance/Rulings/Downloads/CMS1682R.pdf If I am reading this correctly this is great news for Abbott and the libre but not so much for Dexcom if their current price is about $1100 but Dexcom had the $20 bounce on Friday on the news which is good for Dexcom. With Mike C. so active in wanting people to sign the petition for approval I sure hope we will see soon some type of partnership to use the afrezza system in conjunction with the Dexcom CGM for near real-time meal time dosing and control. I feel it was very good news for dexcom. I personally think mnkd and dexcom should enter a co-promotion deal of some kind. It makes sense for both parties.
|
|
|
Post by saxcmann on Jan 17, 2017 8:27:09 GMT -5
I think this is big news! More patients using CGMs only helps prove how afrezza works and keep PWD in control of their blood sugars.
|
|
|
Post by saxcmann on Jan 5, 2017 13:05:27 GMT -5
The answers to these two questions would help give me additional clarity about Mannkind's future. I think the answers would give PB folks some clarity too. If the answer to both of these questions is no, at what point if at all will the answer to these questions be yes? No company with 6 months of cash and facing delisting would hire FTE sales people yet there are many sales and other jobs posted on the career section of Mankind's website. If any of you are friendly with Mike C, perhaps you can shoot him an email. Happy New Year to all of you. Q1 - Has the Touchpoint salesforce that has been selling Afrezza transitioned over to full time Mannkind employees?Q2 - Mannkind has been running ads for additional sales people (AKA: Area Business Managers). Have any of these people been hired and when do they start work?
Ok, I don't know, but I'll guess. By the end of the month the answer to both question will be...Some have:-) I have no idea either, but I like your guess. That's my guess too.
|
|
|
Post by saxcmann on Jan 2, 2017 13:09:10 GMT -5
Slug, my guess is she'll get false roadblocks from her doctor. Most likely her doctor is uneducated and misinformed about afrezza. BP pays big bucks to promote their products and persuade doctors. Her doctor will probably save face and say she'll prescribe but too many roadblocks will lead her to not try it. If your friend is persistent and educated on false objections ahead of time she might have a fighting chance. Here is my list of roadblocks she needs to be prepared for... Insurance does not cover so pay out of pocket. truth...mnkd cares and several discount cards makes this a non issue. Pulmonary issues could still be a problem. Truth...not one case of pulmonary problems (over 10,000 pts) and pulmonary tests ongoing. Exubera failed and afrezza is the same. Truth...afrezza and exubera are both inhalable insulins but very different insulins. Spirometry test requires several appts and delay getting your insulin. Truth...test is extremely easy to perform and endo should have one in office. Dosing is same as Humalog. Doc won't understand dosing so hesitate to prescribe. Truth...afrezza and humalog are not 1 for 1. Have pt go to afrezzajustbreathe to understand more.
Have these points ready for her to discuss. Pt must have strong conviction to pull thru docs roadblocks. Hope this helps...
|
|
|
Post by saxcmann on Dec 26, 2016 22:37:55 GMT -5
sayhey, This is why I used to think that Mannkind's strategy of targeting Endo's and educating them first made sense. However, now I am starting to believe that you have to go right to the patient and create a "pull through" demand for Afrezza. Those doctors who jump on the band wagon will be rewarded while those stuck in the old needle paradigm will fall by the wayside. Same Falcon. Endos need push from patients because docs are misinformed and uneducated about afrezza. Endos rely on high level gurus to teach and disseminate new drug information. Afrezza has none or very little. Big pharma spends billions to get this info to providers. Sanofi and Novo say what about afrezza?...Hmmm? Why would a doctor prescribe if they don't understand it or have false information? Docs simply suggest false roadblocks to patient so they don't have to prescribe it! No insurance coverage...pulmonary issues...multiple appts needed for spirometry test...etc. Patient "pull through" is needed so they'll be forced or they'll lose patients to other providers in my opinion.
|
|